Anti-CTLA-4 antibody therapy is only approved for melanoma and renal cell carcinoma; however, there are multiple ongoing clinical trials with anti-CTLA-4 as one of the combination agents. Here, CTLA4 is linked to hereditary clear cell renal cell carcinoma.